Background-The optimal degree of heparin anticoagulation for peripheral vascular interventions (PVIs) has not been defined. We sought to correlate total heparin dose and peak procedural activated clotting time (ACT) with postprocedural outcomes in patients undergoing PVI. Methods and Results-We studied 4743 patients who received heparin during PVIs in a regional, multicenter registry.
U nfractionated heparin (UFH) is the most commonly used antithrombotic agent in percutaneous peripheral vascular interventions (PVIs) . The availability of a rapid "point of care" assay (the activated clotting time [ACT]) led to the assumption that an optimal level of anticoagulation could be identified in patients undergoing percutaneous coronary interventions (PCIs). 1 However, the optimal heparin anticoagulation in PVI is unknown, with current recommendations empirically based on data from the coronary literature and the TASC II guidelines recommending heparinization to achieve a target ACT between 200 and 250 seconds for PVI. 2 Even in the case of coronary interventions, there is a wide range of "optimal" ACT levels from as low as 200 to 250 seconds to as high as 350 to 375 seconds suggested by different studies, [3] [4] [5] [6] whereas more contemporary data favor a downward shift to the target ACT. 4 -6 
Clinical Perspective on p 601
Adequate dosing with UFH is essential to suppress thrombin generation associated with balloon-induced vascular injury. 7 In contrast, higher doses of heparin are associated with bleeding complications. It is well recognized that bleeding complications, especially those requiring transfusion, are an important predictor of adverse outcome in patients with coronary artery disease who undergo surgical or percutaneous revascularization. 8 -13 The purpose of this study was to evaluate the relationship between the degree of heparin anticoagulation and clinical efficacy as well as bleeding risk in patients undergoing PVI in a regional, multicenter, multidisciplinary registry. We also investigated independent risk factors of periprocedural transfusion because knowledge of these factors would potentially guide a more "conservative" anticoagulation target or an alternative anticoagulant strategy in the subgroups of patients with an exaggerated bleeding hazard.
Methods

Blue Cross Blue Shield of Michigan PVI Registry
Details of the construct, data collection, and data quality assurance for the Blue Cross Blue Shield of Michigan Cardiovascular Consortium Peripheral Vascular Intervention Quality Improvement Initiative (BMC2 PVI), have been described previously. 14 In brief, the BMC2 PVI registry is a prospective, multicenter registry of patients undergoing PVI at the participating hospitals (supplemental material). Endovascular carotid interventions and aortic endografts are not included in the registry because procedural and clinical parameters differ in these patients. A data form is compiled for each procedure. Data quality and the inclusion of consecutive procedures are contractually required and assured by ad hoc queries, random chart review, and a series of diagnostic routines. The data form comprises demographic, clinical and procedural variables, baseline and adjunctive pharmacotherapies, and in-hospital outcome data. A list of standard definitions using the American College of Cardiology Data Standards Committee has been used as reference.
Data Quality Control
All data undergo a 3-step validation process, including manual review for completeness and validity, review of rejected data forms during the import process, and review of forms that fail diagnostic inquiries. All sites are audited twice yearly by a nurse investigator from the coordinating center. In addition to examining cases in which an adverse event was recorded, a random 5% sample of cases is audited for completeness and accuracy. The compliance and accuracy of data in the audits is Ͼ95%. Data that are found to be inaccurate or incomplete are corrected and feedback is provided to the responsible centers.
Study Patients and Definitions
The study cohort for this analysis consisted of 6020 patients undergoing PVI between January 2001 and December 2007. Patients who received periprocedural GP IIb/IIIa antagonists, thrombolytic agents, or who were already on heparin before the procedure, were excluded from the analysis. We also excluded patients whose values for heparin dose or peak ACT were missing because measurement of peak intraprocedural ACT was not standard practice in a majority of labs during the study period. In addition, we excluded patients with recorded ACT Ͻ200 seconds because they would not represent clinically acceptable targets, based on the current practice supported by the coronary literature and the TASC II guidelines, and these patients were more likely to be rebolused with additional heparin after the initial ACT was checked. Because of reported variability in ACT measurements with different point-of-care assays, we restricted our ACT analysis to those using the same ACT device (Hemochron, ITC, Edison, NJ). 15, 16 Thus, 4743 cases were considered for the heparin analysis and 1246 cases for the ACT analysis. Of those, 42.8% had femoropopliteal interventions, 21.4% had iliac interventions, 17.2% had renal interventions, 14.1% had below-knee interventions, and 4.6% had upper extremity interventions. All patients had confirmed peripheral arterial disease, based on 1 or more of the following: abnormal ankle-brachial index, noninvasive imaging studies (ultrasound, computed tomographic angiography, or magnetic resonance angiography) or invasive angiography. Initial analyses were done on 4 clinically relevant categories of heparin dose range and 3 categories of peak ACT range, respectively, suggesting that an increment in the risk of post-PVI drop in hemoglobin Ն3 g/dL and/or transfusion was associated with a total heparin dose Ն60 U/kg and a peak ACT Ն250 seconds (Figures 1 and 2 ). Postprocedural and in-hospital outcomes were compared post hoc between patients who received a total heparin dose Ͻ60 U/kg and Ն60 U/kg. Similarly, outcomes were evaluated between groups with a peak procedural ACT Ͻ250 and Ն250 seconds.
The primary end point for this study was post-PVI bleeding, defined as a drop in postprocedural hemoglobin Ն3g/dL from the preprocedural baseline value or need for transfusion. Preprocedural and postprocedural hemoglobin was drawn within 24 hours before and after the procedure, respectively. Other secondary end points included technical success (defined as successful access, deployment of the device, and Յ30% diameter residual stenosis assessed by angiography after revascularization),procedural success (defined as technical success without periprocedural complications), 17 thrombo- 
Statistical Analysis
Statistical analysis was performed using the SAS 9.1.3 software (SAS Institute, Cary, NC). Descriptive statistics were used to report baseline patient characteristics. All tests used PϽ0.05 as the critical value of statistical significance. The 2 and Fisher exact tests were used to analyze categorical variables. Continuous variables were analyzed using the Student t test and Wilcoxon rank-sum tests as needed. The associations of ACT and weight-adjusted heparin dose with a drop in postprocedural hemoglobin Ն3 g/dL or bleeding requiring transfusion were tested by using multivariate logistic regression models to investigate independent predictors of bleeding. The clinical characteristics included in the model were sex, age (Ն70 years), low body mass index (BMI) (Ͻ18.5 kg/m 2 ), history of myocardial infarction or coronary artery bypass grafting, hypertension, low creatinine clearance (Ͻ60 mL/min per 1.73 m 2 ), hyperlipidemia, diabetes, history of heart failure or TIA/stroke, hybrid vascular surgery and rest pain, preprocedural antiplatelet therapy, treatment with statin, ACT (Ն250 seconds), and heparin dose (Ն60 U/kg). We also used intervention site variables (renal, iliac, femoropopliteal, below-knee, and upper extremity), device variables (balloon, stent, atherectomy, intravascular ultrasound, thrombolysis, cryoballoon, and cutting balloon) and vascular access closure devices (manual or mechanical) in the multivariate regression models. All variables were assessed using forward selection method with a selection criterion of PϽ0.05.
To further adjust for the nonrandomized use of heparin dose Ն60 U/kg and for possible selection bias, a predictive model that adjusted for the propensity to receive heparin Ն60 U/kg was also developed. 18 The propensity score of receiving heparin Ն60 U/kg was calculated using a nonparsimonious logistic regression model. The variables included in the model were age (Ն70 years), sex, low BMI (Ͻ18.5 kg/m 2 ), history of myocardial infarction, hypertension, coronary artery bypass grafting, diabetes, history of heart failure, TIA/stroke, low creatinine clearance (Ͻ60 mL/min per 1.73m 2 , hyperlipidemia, hybrid vascular surgery, rest pain, prior antiplatelet therapy, and intervention site variables. The propensity score was then included as an additional explanatory variable in the final models. Furthermore, we used the Greedy matching technique using a macro to select patients treated with heparin Ն60 U/kg as counterparts to patients treated with heparin Ͻ60 U/kg. 19 More specifically, we sought to match each patient with Ն60 U/kg heparin to a patient with Ͻ60 U/kg, who had a propensity score that was identical to 5 digits. If this could not be done, we then performed a 4-, 3-, 2-, or 1-digit match. Once this threshold was exceeded, the patient with Ն60 U/kg heparin was excluded. In this way, we were able to match 1927 cases with heparin dose Ն60 U/kg to 1927 cases with heparin dose Ͻ60 U/kg. Outcomes were then compared within this propensity-matched cohort. A similar propensity-matched cohort was developed for peak ACT values Ն250 (379 cases) and Ͻ250 seconds (379 cases), and outcomes were compared. We estimated the univariate statistical significance of the effect of higher dose of heparin and higher peak ACT, respectively, on adverse outcomes using generalized estimating equation cluster analysis. 20, 21 Given the multidisciplinary origin of data, to adjust for hospitallevel and physician-level clustering, we compared hierarchical regression modeling with the conventional logistic models to determine the statistical significance of the effect of higher dose of heparin as well as higher peak ACT values on transfusion. [22] [23] [24] This was performed with a random-effects modeling technique. 20, 21 
Results
Among a total of 4743 patients, 2161 patients received heparin Ͻ60 U/kg and 2582 patients received Ն60 U/kg. Of those, 1246 patients had peak procedural ACT recorded and measured with the Hemochron device (Hemochron, ITC, Edison, NJ); 855 of them had ACT Ͻ250 seconds and 391 had ACT Ն250 seconds. The baseline demographic and clinical characteristics are presented in Table 1 for the heparin dose and ACT groups, respectively. In patients receiving higher dose of heparin (Ն60 U/kg), there were more women, current smokers, and higher prevalence of low BMI and low creatinine clearance. Furthermore, in patients receiving the lower dose of heparin (Ͻ60 U/kg), there was a higher prevalence of coronary artery disease, diabetes, hypertension, hyperlipidemia, congestive heart failure, chronic obstructive lung disease, and preprocedural use of antiplatelet therapy with more than 1 agent. Table 2 summarizes the unadjusted rate of postprocedural or in-hospital adverse events for the heparin dose and ACT groups. Technical and procedural success was similar in all groups. Higher weight-adjusted heparin doses were associated with significantly more bleeding complications. Patients with heparin dose Ն60 U/kg had a higher rate of postprocedural hemoglobin drop Ն3 g/dL (7.09% versus 5.09%, respectively, Pϭ0.004) and a higher transfusion rate compared with those with heparin dose Ͻ60 U/kg (4.92% versus 3.15%, respectively, Pϭ0.002). There was no difference in technical and procedural success, MACE, and thromboembolic complications in both groups.
Similarly, a higher ACT was associated with more bleeding and need for transfusion. Patients with a procedural ACT Ն250 seconds had a higher rate of postprocedural drop in hemoglobin Ն3 g/dL (9.7% versus 4.8%, respectively, Pϭ0.0009) and a higher incidence of transfusions compared with the group with ACT Ͻ250 seconds (5.4% versus 2.8%, respectively, Pϭ0.02). Technical and procedural success, MACE, and thromboembolic complications were similar in the two ACT groups.
There were more femoropopliteal PVIs than any other vascular bed treated (Table 3) . A significantly higher number of femoropopliteal and below-knee interventions were performed by using Ͼ60 U/kg of heparin. The majority of the cases were performed with retrograde arterial access with only 12.8% of cases performed with antegrade access. The effect of higher heparin dose and ACT on higher bleeding rates persisted even when cases with retrograde access were analyzed separately.
Although it is difficult to objectively standardize the complexity of the procedure in a multicenter data base, we studied in a separate analysis the heparin dose, bleeding complications, and procedural success stratified according to the location of the procedure-for example, renal, iliac, femoropopliteal, below-knee, and upper extremity-as well †Low creatinine clearance is defined as Ͻ60 mL/min, which is equivalent to stage 3 or more chronic kidney disease according to the National Kidney Foundation definition.
‡Antiplatelets: Aspirin, clopidogrel, ticlopodine, or cilostazol.
as the procedure duration-for example, Յ57 minutes, 58 to 90 minutes, and Ͼ90 minutes. Interventions to the renal arteries had lower heparin doses and bleeding rates as well as higher procedural success, femoropopliteal and iliac interventions had intermediate heparin doses, bleeding rates and procedural success, and below-knee interventions had higher heparin doses and bleeding rates as well as lower procedural success. Similarly, longer procedure duration was intuitively associated with use of higher heparin dose, higher bleeding complications, and lower procedural success. The effect of higher heparin dose on higher bleeding rates persisted even when patients were analyzed separately in short versus long procedure duration. In a multivariate analysis, higher heparin dose (Ն60 U/kg) was found to be an independent predictor of bleeding requiring transfusion (odds ratio [OR], 1.5; 95% confidence interval [CI], 1.11 to 2.0; Pϭ0.01) (Table 4 ); other independent predictors of bleeding were female sex, age Ͼ70 years, prior anemia, prior heart failure, hybrid vascular surgery, rest pain, and below-knee interventions. The c-statistic for this model was 0.799. A separate multivariate logistic model was developed to avoid collinearity between heparin and ACT and also identified ACT Ն250 seconds as an independent predictor of transfusion (OR, 1.9; 95% CI, 1.06 to 3.6; Pϭ0.03). For this model, the c-statistic was 0.812. A significant interaction was observed between heparin dose and ACT levels (OR, 1.29; 95% CI, 1.03 to 1.6; Pϭ0.001).
Manual hemostasis was achieved in 69.7% of the patients. There was no statistical difference in the rate of bleeding between manual hemostasis and use of vascular closure devices. In addition, when we stratified the patients according to sheath size, there was no significant correlation between sheath size and increased bleeding events.
Furthermore, in a propensity-matched cohort ( Table 5 ) in which each patient treated with higher dose of heparin (Ն60 U/kg) was matched to a similar patient treated with lower heparin dose (Ͻ60 U/kg), the higher total heparin dose was associated with significantly higher rates of postprocedural drop in hemoglobin Ն3 g/dL (7.01% versus 5.14%, respectively, Pϭ0.01) and transfusion (4.67% versus 3.17%, re- spectively, Pϭ0.016). Similarly, in a propensity-matched, risk-adjusted model for the ACT groups (Ն250 seconds and Ͻ250 seconds), patients with a higher ACT (Ն250 seconds) had significantly higher rates of postprocedural drop in hemoglobin (10.03% versus 5.8%, Pϭ0.03) and a trend toward more transfusion (5.54% versus 2.9%, Pϭ0.07) ( Table 5 ). Importantly, there were no differences with respect to technical and procedural success, MACE, and thromboembolic complications in all groups. A separate propensity-score matching analysis by adding intervention sites (renal, iliac, femoropopliteal, below-knee, and upper extremity) to the models demonstrated similar findings.
The heparin patient cohort (nϭ4743) data were obtained from 7 different hospitals involving 75 physicians, whereas the ACT cohort (nϭ1246) data derived from 7 hospitals involving 59 physicians. To adjust for hospital-level and physician-level variations, a hierarchical regression model was performed to determine the relationships between physician-and hospital-level characteristics for each of the outcomes. The physician-and hospital-level factors did not have any impact on the effect of higher dosage of heparin leading to transfusion as determined by similar ORs derived from the hierarchical (OR, 1.4; 95% CI, 1.14 to 1.82; Pϭ0.002) and logistical (OR, 1.5; 95% CI, 1.1 to 2.0; Pϭ0.01) models. Similarly, the effect of higher ACT remained significant in the hierarchical (OR, 2.2; 95% CI, 1.3 to 3.7; Pϭ0.0003) as well as in the logistic model (OR, 1.9; 95% CI, 1.06 to 3.6; Pϭ0.03).
Discussion
This analysis of prospectively collected individual patient data represents the largest study correlating the degree of Hgb indicates hemoglobin; CHF, congestive heart failure; and NS, nonsignificant. *The ACT was tested using a separate multivariate logistic regression analysis, excluding the heparin dose, to avoid significant collinearity between the 2 variables. †An interaction term was created for heparin and ACT and added to the multivariate models to determine interactions between heparin dose and ACT. anticoagulation with heparin and early postprocedural outcomes in PVI. The key findings of our study were that during PVI, a higher total heparin dose (Ն60 U/kg) and a peak procedural ACT Ն250 seconds were predictors of postprocedural bleeding events. Moreover, the technical and procedural success was high and the rate of thromboembolic complications was low and did not differ between groups. These findings suggest that use of weight-based heparin dosing (initially, up to 60 U/kg) with a target ACT Ͻ250 seconds may improve outcomes in PVI.
A previous single-center, retrospective study evaluated in-hospital complications of peripheral interventions in which UFH was the primary anticoagulant in 131 patients (with ACT recorded in 114) and reported a nonsignificant trend toward higher adverse events with increased weight-based doses of heparin and no significant relationship between ACT and adverse events, although there was a relationship between heparin dosage and ACT level. 25 The rate of major bleeding in this study increased from 2.1% with heparin dose 30 to 54.9 U/kg to 5.4% with heparin dose 55 to 99.9 U/kg. This is in agreement with our findings, in which patients with heparin dose Ն60 U/kg had higher rates of drop in hemoglobin of Ն3 g/dL (7.09%) and transfusion (4.92%) compared with those with heparin dose Ͻ60 U/kg (5.09% and 3.15%, respectively).
Most of the data related to the optimal degree of anticoagulation with heparin for arterial percutaneous interventional procedures are extrapolated from the coronary literature. A previous meta-analysis of 6 randomized, controlled trials of novel adjunctive antithrombotic regimens for PCI, in which UFH constituted the control arm, demonstrated an "optimal" target of ACT in the range of 350 to 375 seconds that provided the lowest composite ischemic event rate. 3 However, this degree of anticoagulation was associated with a higher incidence of bleeding, increasing from 8.6% within an ACT range of 325 to 350 seconds to 12.4% at ACT of 350 to 375 seconds.
Subsequent and more contemporary studies favored a downward shift in the target ACT levels in PCI. 4 -6 Accordingly, a post hoc analysis of the population enrolled in the ESPRIT trial (Enhanced Suppression of the Platelet GP IIb/IIIa Receptor with Integrilin Therapy), comparing the use of eptifibatide versus placebo in patients undergoing PCI with stent, demonstrated that the incidence of ischemic events did not increase as ACT decreased at least to a level of 200 seconds, whereas bleeding events did increase with increasing ACT levels. 4 Notably, the recommended initial bolus of heparin dose in this trial was 60 U/kg, which is the cutoff that we used in our study. The ESPRIT investigators concluded that an ACT level of 200 to 250 seconds is reasonable in terms of efficacy and safety with the use of contemporary technology and pharmacotherapy. Within the same conceptual framework, a large pooled analysis of the UFH-treated patients enrolled in 4 recent large, randomized trials using a median ACT of 276 seconds demonstrated that in patients undergoing PCI with frequent stent and potent platelet inhibition use, ACT does not correlate with ischemic complications and has a modest linear association with bleeding complications, suggesting that lower ACT values do not appear to compromise efficacy while increasing safety. 6 Notably, these trials assessed the concurrent use of UFH and GPIIb/IIIa antagonists, whereas in our study the use of UFH alone was evaluated. Therefore, even in the absence of the use of GP IIb/IIIa antagonists, a lower ACT or heparin dose in PVI does not result in more thromboembolic complications.
Although it appears simple to extrapolate the evidence from coronary interventions and apply it to the peripheral arteries, the relationship between heparin dosing-ACT levels and bleeding complications, as well as procedural outcomes, may be less evident in straightforward cases of coronary stenting than in more prolonged and complex peripheral arterial procedures. Therefore, the results of our analysis provide further insight in defining the optimal degree of heparin anticoagulation during PVI. In addition, it is well documented that bleeding complications, especially those requiring transfusion, remain an independent, strong predictor of adverse outcomes in patients undergoing PCI. 8 -11,13,26 Even though there is no current evidence on the prognostic implications of bleeding complications in PVI, patients with peripheral arterial disease represent an equivalent high-risk cohort, often with significant comorbidities, such as coronary artery disease, diabetes, and renal dysfunction. Therefore, it is essential to minimize bleeding risk while maintaining a safe anticoagulation level during PVI.
Although our registry analysis establishes the evidence base for a higher safety threshold for a target ACT in PVI, the question of a lower safe ACT threshold remains to be answered. It is possible that lower levels of anticoagulation may be sufficient and safe in PVI, given the large vessel size, especially in those patients already on dual antiplatelet therapy. Within this concept, a randomized, double-blind, prospective study demonstrated that in the treatment of uncomplicated coronary lesions and in the presence of dual antiplatelet therapy with aspirin and clopidogrel, elective PCI could be safely performed without systemic anticoagulation and was associated with a reduced incidence of bleeding complications. 27 However, this interesting hypothesis has not been studied yet in PVI, it cannot be answered within the setting of a "real-life" registry using the current guidelinedriven standards of care, and it will require a future randomized, prospective clinical study to address this question.
Beyond the heparin dose and the ACT level, in the multivariate analysis we found that female sex, creatinine clearance Ͻ60 mL/min per 1.73m 2 age Ͼ70 years, preprocedural anemia, history of heart failure, hybrid vascular surgery, rest pain, and below-knee interventions were independent predictors of higher postprocedural bleeding risk. These findings are consistent with those from 2 large retrospective databases of patients undergoing PCI 13, 28 and a registry of 24 045 patients with acute coronary syndromes from the Global Registry of Acute Coronary Events (GRACE). 29 Less aggressive anticoagulation, or use of an alternative anticoagulant strategy such as a direct thrombin inhibitor, may decrease the incidence of bleeding complications in these subgroups of high-risk patients. 30 -33 
Limitations
Our findings are based on observational, prospectively collected data, and, inevitably, there were significant differences in the demographic and clinical characteristics. Although we adjusted using multivariate logistic regression and propensity analysis, it is possible that other confounding factors may have influenced outcomes. In addition, this database spans a period of 7 years and encompasses a heterogeneous group of endovascular interventions and advancing interventional techniques as well as reflecting multiple institutions and operators. Even though we have tried to adjust for hospitaland operator-specific clustering by using hierarchical regression techniques, operator-specific variations in procedural outcomes as well as in heparin dosing and ACT target are also inherent limitations of our study. However, this represents a "real-life" data base, and these procedures will continue to be performed by multiple operators from different specialties, including interventional cardiologists, interventional radiologists, and vascular surgeons as well as in both academic and private institutions. Because of inherent differences in the measurement of ACT by different ACT devices 15, 16 and to be consistent, we have restricted our ACT data to those measured by the Hemochron device only, which was the most common device used in our registry. This obviously limits our ability to generalize the findings to other devices. It should be also noted that the study cohort for this analysis consisted of patients undergoing PVI using the old formulation of heparin available in the United States. However, effective as of October 2009, a new formulation of heparin is available in the United States, and, according to the FDA public health alert, there is an approximate 10% decrease in the potency of the "new heparin" compared with the "old heparin." 34 This dose adjustment should be taken into consideration when the "new heparin" is used. Furthermore, the suggested weight-based heparin dosing (initially up to 60 U/kg) with a target ACT of Ͻ250 seconds, as opposed to "empirical" dosing, should serve as a general guide for heparin anticoagulation in PVI and should not substitute for the individualization of dose in specific subgroups of patients who are at higher bleeding risk, necessitating a more conservative dose, or, conversely, are resistant to heparin requiring higher doses.
Conclusion
Notwithstanding these limitations, this is the first large-scale study to evaluate the optimal degree of heparin anticoagulation in PVI. This study suggests that use of weight-based heparin dosing (initially up to 60 U/kg) with a target ACT Ͻ250 seconds in PVI may minimize the bleeding risk without compromising procedural success or increasing thromboembolic complications. Future prospective, randomized studies are warranted to further validate these findings and potentially establish a lower safe ACT threshold for peripheral vascular interventions.
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